Evidence map›Paper›PMID 40986299›Full record

ArticleJAMA network open2025

Premenstrual Disorders and Quality of Life in Sweden.

Qiwei Wang, Rebecka Keijser, Yufeng Chen, Hang Yu, Elgeta Hysaj, Sara Hägg, Unnur A Valdimarsdóttir, Elizabeth Bertone-Johnson, Jurate Aleknaviciute, Donghao Lu

Abstract read
In one paragraph

Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qiwei WangUnit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Rebecka KeijserUnit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Yufeng ChenUnit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Hang YuUnit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Elgeta HysajUnit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Sara HäggDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Unnur A ValdimarsdóttirUnit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Elizabeth Bertone-JohnsonDepartment of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts Amherst.
Jurate AleknaviciuteDepartment of Psychiatry, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
Donghao LuUnit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Premenstrual disorders (PMDs), including premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD), are associated with significant physical and psychological burdens. However, their associations with quality of life (QOL) remain insufficiently studied, particularly with limited consideration of comorbidities and potential confounders. Objective: To assess the QOL among women with PMDs compared with women without PMDs in Sweden. Design, Setting, and Participants: This cross-sectional study included participants from the LifeGene cohort, a population-based longitudinal study with linkage to national health care registers. Participants were women aged 15 to 60 years. Data were collected from October 2009 to May 2018 and analyzed from June 2024 to January 2025. Exposures: PMDs were ascertained using a modified Premenstrual Symptoms Screening Tool, supplemented by diagnoses recorded in Swedish health care registers. Main Outcomes and Measures: QOL was assessed using the EuroQol 5-Dimensions 3-Levels scale including 5 dimensions: mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. The primary outcome was the total QOL score, with additional analyses excluding the anxiety or depression and pain or discomfort dimensions. Associations between PMDs and total QOL score were evaluated using linear regression models, adjusting for age, socioeconomic status, and potential confounders. Analyses were further stratified by the history of comorbidities. PMS, PMDD, and each QOL dimension were also examined separately. Results: In this study of 17 284 women, at a mean (SD) age of 32.4 (8.1) years, 1813 women (10.5%) met the criteria for PMDs. Women with PMDs had significantly lower QOL compared with those without PMDs (mean z score difference: 0.21; 95% CI, 0.17-0.26). This association persisted in the prospective analysis (mean z score difference: 0.34; 95% CI, 0.24-0.45) or after excluding the anxiety or depression and pain or discomfort dimension. PMDD appeared to have a stronger association with reduced QOL than PMS. In the analysis of individual QOL dimensions, PMDs were strongly associated with endorsing anxiety or depression (PR, 1.31; 95% CI, 1.25-1.37) and pain or discomfort (PR, 1.14; 95% CI, 1.08-1.21). Conclusions and Relevance: In this cross-sectional study of women in Sweden, PMDs, particularly PMDD, were significantly associated with reduced QOL, independent of potential confounders and comorbidities. These findings highlighted the need for both health care and social support to better manage the disease and improve the overall QOL of affected women.

Indexed as

Premenstrual Dysphoric DisorderPremenstrual SyndromeQuality of LifeAdolescentAdultCross-Sectional StudiesFemaleHumansLongitudinal StudiesMiddle AgedSwedenYoung Adult

Identifiers

PMID40986299
PMCPMC12457971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.